HeartFlow
HTFLHTFL · Stock Price
Historical price data
Overview
HeartFlow's mission is to transform coronary artery disease from a leading cause of death into a proactively managed chronic condition. The company has achieved remarkable commercial success, with its technology deployed in over 1,800 institutions, used on 600,000+ patients, and secured near-universal U.S. insurance reimbursement. Its strategy centers on expanding its AI-powered platform from a diagnostic tool into a comprehensive, longitudinal management system for CAD, leveraging a vast and growing clinical evidence base.
Technology Platform
AI-powered software platform that converts standard coronary CT angiography scans into personalized 3D models, simulating blood flow (FFR CT) and quantifying plaque to provide integrated anatomical and physiological insights.
Pipeline
3| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Evolocumab | Coronary Artery Disease | Approved | |
| Rosuvastatin 40mg + Placebo | Coronary Artery Disease | Pre-clinical | |
| High intensity lipid lowering | Coronary Artery Disease | Pre-clinical |